Blog

Cassava Sciences Stock Plummets 85% After Failed Alzheimer’s Trial Results and Ongoing Investigations

Hannah Perry | November 26, 2024

Cassava Sciences’ Stock Craters After Alzheimer’s Disease Trial Fails to Meet Its Goals A Severe Decline in Market Value Cassava Sciences Inc.’s stock experienced a dramatic decline of **85%** on Monday, setting the stage for its most significant one-day drop to date. This plunge followed the announcement that the company’s clinical trials for a treatment…

Eli Lilly Emerges as Hedge Funds’ Top Healthcare Pick Amidst Rapid Growth and AI Innovations

Hannah Perry | November 25, 2024

Eli Lilly’s Breakthroughs: Hedge Funds’ New Healthcare Favorite The Healthcare Sector: Growth, Innovation, and the Impact of AI The healthcare sector is undergoing a period of remarkable growth and innovation, heavily influenced by advancements in medical technology. Unlike pharmaceuticals, which focus on chemical processes, medical devices employ physical or mechanical means for disease prevention, diagnosis,…

Viking Therapeutics: Transforming Treatment for Metabolic Diseases Beyond Weight Loss

Hannah Perry | November 22, 2024

Viking Therapeutics: A Multifaceted Biotech Player Beyond Weight-Loss Viking Therapeutics Inc. (VKTX) has recently garnered attention, not just for its promising obesity pill, but also for a key product candidate in its pipeline—a treatment for the liver disease known as metabolic dysfunction-associated steatohepatitis, or MASH. This development has drawn enthusiastic responses from investors and analysts…

4 Undervalued Biotech Stocks to Invest In Amid Overblown Healthcare Concerns

Hannah Perry | November 21, 2024

4 Biotech Bets to Make as Healthcare Fears Become Overblown The trading environment on Tuesday faced significant headwinds as concerns over the escalating conflict in Ukraine took center stage. The unsettling news included U.S.-supplied missiles being used against targets further away from the border and Russia’s altering of its nuclear doctrine. Despite this rocky start,…

RFK Jr.’s Nomination to HHS: What Investors Need to Know about Market Concerns and Healthcare Impacts

Hannah Perry | November 20, 2024

RFK Jr. Nomination Sparks Concerns in Markets The recent announcement of President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services (HHS) has ignited a whirlwind of reactions from investors. This unorthodox pick, among other controversial appointments, has left many grappling with the potential repercussions for markets,…

Biotech Stocks Set to Thrive as FDA Eases Drug Approval Process

Hannah Perry | November 19, 2024

Biotech Stocks Poised for Growth Amid Easing FDA Regulations Introduction to Biotech Investing Investing in biotech stocks has always been a challenging endeavor, primarily because the success of these investments hinges on obtaining regulatory approval for drugs. Recently, however, there’s a glimmer of hope on the horizon for investors, as the U.S. Food & Drug…

Eli Lilly and Novo Nordisk: Can They Overcome Ozempic Copycats and Meet Rising Demand?

Hannah Perry | November 18, 2024

Eli Lilly and Novo Want to Shake off Ozempic Copycats: Are They Ready to Meet Demand? Pharmaceutical giants Eli Lilly and Novo Nordisk are facing an unprecedented challenge as they attempt to maintain their market presence in the rapidly evolving landscape of diabetes and obesity drugs. Known as GLP-1s, medications like Ozempic and Zepbound not…

Pfizer’s Oncology Strategy: Driving Growth and Innovation in Cancer Treatment and Prevention

Hannah Perry | November 14, 2024

The Oncology Bet Is Already Paying Off For Pfizer With the waning of the Covid-19 pandemic, pharmaceutical companies have turned their focus toward oncology in search of their next growth narrative. Pfizer Inc (PFE) has reported a compelling performance in its third quarter, showcasing a robust 14% revenue growth on an operational basis, significantly attributed…

Healthcare Provider Bankruptcies Persist in 2023 2024 Outlook Shows Minimal Improvement

Hannah Perry | November 13, 2024

Healthcare Provider Bankruptcy Filings Continue Despite Expected Decrease As we move into 2024, the trend of healthcare providers filing for Chapter 11 bankruptcy appears to persist, even with projections indicating a potential decline in such cases. According to a recent report by healthcare restructuring firm Gibbins Advisors, a total of 58 healthcare companies with liabilities…

Three Biotech Stocks to Consider After Strong Earnings Reports

Hannah Perry | November 12, 2024

Three Biotech Stocks to Buy After More-Than-Solid Quarters As the markets continue to thrive following last week’s post-election rally, the S&P 500 index has recently crossed the significant milestone of 6,000. Investors are feeling optimistic, with stocks pushing deeper into uncharted territory based on a variety of valuation metrics. In light of this, I’ve decided…

« Previous PageNext Page »